Healio

Once-monthly octreotide provides sustained acromegaly control with fewer injections

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
MedPage Today

Investigational Once-Monthly Injectable Boosts Response Rate in Acromegaly

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...
Nasdaq

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* ...
ascopubs.org

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome Joseph Rubin, Jaffer Ajani, William Schirmer, Alan P. Venook, Ronald ...
Nasdaq

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

LUND, Sweden, April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
Monthly Prescribing Reference

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
FierceBiotech

Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study

On Track To Initiate Pivotal Trial Of Octreolin TM (An Oral Form Of Octreotide Acetate) In Patients With Acromegaly By Year End 2010 NEW YORK and JERUSALEM, June 14 /PRNewswire/ -- Chiasma, Inc., a ...
FOX8 Cleveland

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient reported treatment ...
Monthly Prescribing Reference

First Generic Version of Sandostatin LAR Depot Now Available

The first generic version of Sandostatin ® LAR Depot is now available from Teva Pharmaceuticals. Teva’s Octreotide Acetate for Injectable Suspension is indicated for treatment in patients who have ...
Seeking Alpha

Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New ...
ascopubs.org

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome

Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome Joseph Rubin, Jaffer Ajani, William Schirmer, Alan P. Venook, Ronald ...
Seeking Alpha

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

First subcutaneous, once-monthly octreotide for treatment of acromegaly For convenient self-administration with a pre-filled autoinjector pen LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ ...